DermBiont
PrivateLast Round
Series B
Oct 24, 2023
Total Funding Raised
$76.65M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
DermBiont operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in October 2023.
DermBiont is a biotechnology company that develops targeted topical therapeutics for rare disease oncology and aesthetic dermatology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DermBiont Comparables
Compare DermBiont with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PellePharm | 88% | |
| NFlection Therapeutics | 84% | |
| AOBiome Therapeutics Inc. | 78% |
For institutional investors. Book with your work email.
DermBiont Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 24, 2023 | ||||
| Debt | Mar 28, 2023 | ||||
| Series A Extension | Dec 21, 2021 | ||||
| Series A | Jun 18, 2019 | ||||
| Accelerator | Apr 26, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
DermBiont Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Viking Global Investors | Series B, Series A Extension, Series A |
| Toba Capital | Series A Extension, Series A |
| Zola Global | Series A |
| Pivotal bioVenture Partners | Series A Extension |
| Civilization Ventures | Series B, Series A Extension |
| Double Point Ventures | Series B |
| Illumina Accelerator | Accelerator |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 125% MoM, reaching 2.2K.
- Jun 22, 2026
Monthly visitors increased 44% MoM, reaching 1.3K.
For institutional investors. Book with your work email.
DermBiont Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about DermBiont's valuation, stock price, and market status.
Is DermBiont a public or private company?
DermBiont is a private company.
What is the current stock price of DermBiont?
DermBiont is a private company, so its shares have no public market price. Caplight tracks DermBiont's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is DermBiont worth (valuation)?
Valuation information for DermBiont is not publicly available.
Can I buy DermBiont stock?
DermBiont shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was DermBiont's last funding round?
DermBiont's most recent funding round was Series B on October 24, 2023.
Who are the main investors in DermBiont?
Key investors in DermBiont include Viking Global Investors, Toba Capital, Zola Global, Pivotal bioVenture Partners, Double Point Ventures.
Will DermBiont IPO soon?
No public IPO plans have been announced for DermBiont.
How can I track DermBiont secondary market activity?
Caplight tracks bids, offers, and trades in DermBiont's shares on secondary markets.